



Result of 2018 Annual General Meeting

Tiziana Life Sciences plc held its Annual General Meeting ('AGM') at 10:00 am on 25 June 2018 at offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.

All resolutions proposed to shareholders were duly passed. The proxy votes lodged in advance of the meeting, which were the only votes cast for the purposes of the AGM, are summarised below:

Resolution	In Favour			Discretion			Against			Withheld	
	Votes	%	Items	Votes	%	Items	Votes	%	Items	Votes	Items
1	63,396,309	99.98	23	1,022	0.01	5	1,335	0.01	3	150	1
2	63,396,454	99.98	23	1,022	0.01	5	1,340	0.01	4	0	0
3	63,396,454	99.98	23	1,022	0.01	5	1,340	0.01	4	0	0
4	63,396,450	99.98	22	1,026	0.01	6	1,340	0.01	4	0	0
5	63,396,126	99.98	24	1,022	0.01	5	1,335	0.01	3	333	1
6	63,396,055	99.98	22	1,022	0.01	5	1,340	0.01	4	399	2
7	63,396,388	99.98	22	1,022	0.01	5	1,340	0.01	4	66	1
8	63,396,101	99.98	21	1,022	0.01	5	1,344	0.01	4	349	3

NB: Percentage of votes cast excludes Withheld votes

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.